Surface Logix To Present At The Piper Jaffray Health Care Conference
BOSTON, Nov. 27 /PRNewswire/ -- Surface Logix Inc. announced that Jim Mahoney, President and Chief Executive Officer, will present an update of the company's drug development pipeline at the Piper Jaffray Health Care Conference on November 29, 2006, at 11:10 a.m. Eastern time from The Pierre Hotel in New York City.
Surface Logix Inc. currently has two programs in human clinical trials with a third program approaching its initial regulatory submission. Mr. Mahoney will discuss the latest results for SLx-2101, currently in Phase IIa, a second generation PDE5 inhibitor designed to address cardiovascular indications, including Raynaud's Syndrome and Hypertension; and SLx-4090, soon to be in Phase IIa, a first-in-class enterocyte specific MTP inhibitor targeting unmet needs in dyslipidemia and metabolic disorders.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to create new small molecule drugs that are optimized to meet the challenges of human physiology. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases. For more information, please visit http://www.surfacelogix.com.
Contact: Warwick Tong MB ChB Surface Logix Inc. Senior Vice President, Commercial Development 617.746.8505 Media: Kari Watson MacDougall Biomedical Communications Inc. kwatson@macbiocom.com 508.647.0209
Surface Logix Inc.CONTACT: Warwick Tong MB ChB, Senior Vice President, CommercialDevelopment of Surface Logix Inc., +1-617.746.8505; or Media: Kari Watsonof MacDougall Biomedical Communications Inc., for Surface Logix Inc.,+1-508-647-0209, kwatson@macbiocom.com
Web site: http://www.surfacelogix.com/